医保国谈药&#x0201c;双通道&#x0201d;管理机制成效与展望

孙焕征; 曹人元; 任今今; 曹庄

doi:10.19546/j.issn.1674-3830.2023.1.002

中国医疗保险 ›› 2023, Vol. 0 ›› Issue (1) : 12-15. DOI: 10.19546/j.issn.1674-3830.2023.1.002

深度聚焦

医保国谈药“双通道”管理机制成效与展望

孙焕征, 曹人元, 任今今, 曹庄

作者信息 +

Effect and Prospect of the Dual-channel Management Mechanism of National Medical Insurance Negotiation Drugs

Author information +

文章历史 +

摘要

为解决谈判药品落地问题,满足参保人合理用药需求,国家建立“双通道”管理机制。本文通过梳理分析各地区“双通道”政策实施情况,总结我国目前“双通道”管理成效与问题,探究完善“双通道”管理机制的有效措施,以期为我国“双通道”管理机制建设提供参考。

Abstract

In order to solve the problem of negotiated drug delivery and meet the reasonable drug use needs of the insured, China has established a dual-channel management mechanism. Through analyzing the implementation of the dual-channel policy in various regions, this paper summarizes the effectiveness and problems of the current dual-channel management in China, and explores effective measures to improve the dual-channel management mechanism, with a view to providing reference for the construction of the dual-channel management mechanism in China.

导出引用

孙焕征, 曹人元, 任今今, 曹庄. 医保国谈药“双通道”管理机制成效与展望[J]. 中国医疗保险. 2023, 0(1): 12-15 https://doi.org/10.19546/j.issn.1674-3830.2023.1.002

Effect and Prospect of the Dual-channel Management Mechanism of National Medical Insurance Negotiation Drugs[J]. China Health Insurance. 2023, 0(1): 12-15 https://doi.org/10.19546/j.issn.1674-3830.2023.1.002

中图分类号： F840.684 C913.7

参考文献

[1] 国家医疗保障局,国家卫生健康委.关于建立完善国家医保谈判药品“双通道”管理机制的指导意见[EB/OL].http://www.nhsa.gov.cn/art/2021/5/10/art_37_5023.html,2022-12-28.
[2] 谢家隆,叶艮英,罗振光,等.“双通道”机制实施背景下医院药品管理系统改造升级策略及效果——以东莞某三甲医院为例[J].中国医疗保险,2022(04):101-103.
[3] 李婵,邹佳,徐焦,等.“双通道”模式下S省国谈药可获得性分析[J].中国医疗保险,2022(11):54-59.
[4] 山东省人民政府.山东省政府新闻办新闻发布会介绍国家医保谈判药品“双通道”管理机制建设情况[EB/OL].http://www.shandong.gov.cn/vipchat1//home/site/82/4025/article.html,2022-12-28.
[5] 李燕,丁锦希,李伟,等.医保药品目录竞价准入与谈判准入的差异性分析[J].世界临床药物,2021,42(06):514-518.
[6] 郑解元,梁嘉莹.“双通道”处方流转平台建设与探讨[J].海峡药学,2022,34(10):156-158.